|
1. A composition comprising a sodium/glucose co-transporter 1 inhibitor and a vascular endothelial growth factor receptor 2 inhibitor, wherein the sodium/glucose co-transporter 1 inhibitor is sotagliflozin; and wherein the vascular endothelial growth factor receptor 2 inhibitor is selected from at least one of apatinib, axitinib, nintedanib, cediranib, pazopanib hydrochloride, sunitinib malate, brivanib, cabozantinib, brivanib alaninate, lenvatinib, regorafenib, ENMD-2076, ENMD-2076 L-(+)-tartaric acid, tivozanib, ponatinib, fruquintinib, telatinib, taxifolin, pazopanib, cabozantinib malate, vitamin E, regorafenib monohydrate, nintedanib ethanesulfonate salt, lenvatinib mesylate, cediranibmaleate, 4-[(1E)-2-[5-[(1R)-1-(3,5-dichloro-4-pyridyl)ethoxyl-1H-indazol-3-yl]vinyl]-1H-pyrazole-1-ethanol, sunitinib, sitravatinib, anlotinib dihydrochloride, sorafenib, vandetanib and a monoclonal antibody medicament targeting vascular endothelial growth factor receptor; wherein the sodium/glucose co-transporter 1 inhibitor is at a dosage of 1 to 100 mg/kg and the vascular endothelial growth factor receptor 2 inhibitor is at a dosage of 10 to 500 mg/kg.
|